arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Boundless Bio, Inc.

BOLD
$2.60 ▼ -0.11 (-4.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Boundless Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $58.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -50.9% ↘
FCF / Share $-2.11 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-58.20M
↑ +11.0% —
FCF / Share Free cash flow per share
$-2.11
↑ +43.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 3 years · 14 quarters